ArticleClinicoEconomics and outcomes research : CEOR2023

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States.

Lauren Ramjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.